Inhaled cell particles for lung disease in IgG4-related disease or scleroderma
Part of Immune system & allergy, Skin clinical trials.
This study tests a new treatment that is breathed in as a mist (nebulized) and uses tiny particles from cells (called extracellular vesicles) to help calm the immune system. It is for people with IgG4-related disease or systemic sclerosis that have lung problems, and may help reduce inflammation and improve breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have either IgG4-related disease or systemic sclerosis (scleroderma) that has been diagnosed for at least 6 months.
- Your disease has affected your lungs, such as lung scarring, nodules, or airway changes, as seen on a CT scan.
- You are willing to use effective birth control during the study and for 6 months after the last dose.
- You have not had stem cell or extracellular vesicle treatment before.
- You do not have other serious autoimmune diseases, active infections (like hepatitis, HIV, or tuberculosis), or recent heart or blood vessel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.
This trial tests a new inhaled therapy made from tiny particles derived from placental cells, which may help reduce scarring in the lungs. It is a phase 1 study, so the main goal is to check safety and see if the treatment has any effect on IPF.
This study tests an experimental treatment using tiny particles from human stem cells, given through a nebulizer (breathing mist). It aims to see if this treatment is safe and can help improve lung function in people with interstitial lung disease (lung scarring).
This trial tests a new treatment using stem cells from umbilical cords to help people with scleroderma-related lung disease. It aims to see if the treatment can slow down or improve lung scarring and breathing problems.
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.